Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Corteva

CTVA NYSE Fertilizers & Agricultural Chemicals Financials FY2018–FY2025

Corteva had $17.4B of revenue in fiscal 2025, up 2.9% on the year before. Over five years, revenue changed +4.1% a year on average.

Add to portfolio Download report
Today
4.0%
Previous close
$12.45
Market cap
$8.0B
P/E
7.9x
Fair value (model)
$37.99 +218% vs price
52-week range
$11.92 $90.51

Last close Β· Oct 26, 2026

$11.95

βˆ’$51.71 (βˆ’81.23%) past year

Share price

Corteva
Value it Compare

What Corteva does

CTVA Β· Fertilizers & Agricultural Chemicals

From its latest annual report

No business description yet.

Filing details

Legal name
Corteva, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
β€”
Accession Β· CIK
0001755672-26-000004 Β· 0001755672

Earnings calendar Β· Corteva

Every quarter, companies publish how much they sold and earned. These are the days Corteva did it, and the next one. Share prices often move a lot on those days.

Next results

November 11, 2026

Wednesday Β· in 15 days

Time
After the market closes
Covers
Period ended Sep 30, 2026
Expected EPS
$0.09
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Jul 30, 2026 Q2 '26 After the market closes 8-K β†—
May 5, 2026 Q1 '26 After the market closes 8-K β†—
Feb 3, 2026 Q4 '25 After the market closes 8-K β†—
Oct 1, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 6, 2025 Q2 '25 After the market closes 8-K β†—
May 7, 2025 Q1 '25 After the market closes 8-K β†—
Feb 5, 2025 Q4 '24 After the market closes 8-K β†—
Nov 6, 2024 Q3 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Corteva’s latest annual report (fiscal 2025). Here is what stands out:

5 strengths

1.Sales and profit

See section β†’
  • Corteva had $17.4B of revenue in fiscal 2025, up 2.9% on the year before. Over five years, revenue changed +4.1% a year on average.
  • Corteva made $1.1B of net profit in fiscal 2025.

2.Cash and shareholders

See section β†’
  • Free cash flow was $2.8B in fiscal 2025, 16.2% of revenue.
  • Corteva returned $1.5B to shareholders in fiscal 2025, 55% of free cash flow. The diluted share count fell 2.1%.
  • In the last 12 months, insiders sold $0.6M of shares on the open market and bought none.

3.Financial health

See section β†’
  • Corteva has $2.0B more cash than debt.
  • Its return on capital was 5.8%: every 100 invested in the business earned about 6 in a year.
  • Corteva passes 8 of 9 financial health tests (Piotroski F-score).

4.Price and value

See section β†’
  • At $11.95 a share, the company is worth $8.0B: 7.9 times its earnings of the last four quarters.
  • Corteva grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 0 of 2.

Corteva in 30 seconds

Good So-so Weak

So-so

Are sales growing?

+2.9%

Only a little. Sales grew 2.9% last year.

So-so

Does it make a profit?

6.3%

A little. It keeps 6.3% of every sale as profit.

Good

Does profit turn into cash?

16.2%

Yes. 16.2% of sales ends up as free cash.

Good

Is debt under control?

Net cash

Yes. It has more cash than debt.

Good

How healthy are the accounts?

8 / 9

Solid. It passes 8 of 9 health tests.

For information

How is the share priced?

7.9x

One share costs 7.9 times its yearly profit per share. Typical for its sector: 20.6x.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$8.0B
Oct 26 close
P/E Last close divided by diluted earnings per share over the last four quarters.
7.9x
On $1.52 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Corteva had $17.4B of revenue in fiscal 2025, up 2.9% on the year before. Over five years, revenue changed +4.1% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Corteva made $1.1B of net profit in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $2.8B in fiscal 2025, 16.2% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA Β· Its return on capital was 5.8%: every 100 invested in the business earned about 6 in a year.

See the full section β†’

About these figures. Total debt is the balance sheet's long-term debt plus its current debt line.

Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

KIRA summarises the numbers

  • Corteva had $17.4B of revenue in fiscal 2025, up 2.9% on the year before.

    Over five years, revenue changed +4.1% a year on average.

Revenue

Revenue

Margins, % of revenue

Gross Operating Net FCF

Margins, % of revenue

Gross Operating Net FCF

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Net income and earnings per share

Loss periods are shown in red.

KIRA summarises the numbers

  • Corteva made $1.1B of net profit in fiscal 2025.

Net income

Net income

Diluted EPS

Diluted EPS

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

KIRA summarises the numbers

  • Free cash flow was $2.8B in fiscal 2025, 16.2% of revenue.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Dividends, buybacks and share count

KIRA summarises the numbers

  • Corteva returned $1.5B to shareholders in fiscal 2025, 55% of free cash flow.

    The diluted share count fell 2.1%.

Dividends and buybacks

Dividends Buybacks

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

KIRA summarises the numbers

  • In the last 12 months, insiders sold $0.6M of shares on the open market and bought none.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.6M

1 insider

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Feb 20, 2026 Brian TitusSee Remarks Sold 8,311 $76.55 $0.6M Form 4

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Corteva can carry it.

KIRA summarises the numbers

  • Corteva has $2.0B more cash than debt.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $4.5B$3.3B$2.7B$3.2B$4.5B
Debt incl. finance leases $1.1B$1.3B$2.5B$2.7B$2.6B
Net debt / EBITDA βˆ’1.0xβˆ’0.7xβˆ’0.1xβˆ’0.2xβˆ’0.6x
Debt / equity 0.0x0.1x0.1x0.1x0.1x
Interest coverage 79.2x19.1x5.7x6.5x10.4x
Current ratio 1.6x1.6x1.6x1.5x1.4x
Quick ratio 1.1x0.9x0.9x0.9x1.0x
Total assets $42.3B$42.6B$43.0B$40.8B$42.8B
Total liabilities $16.7B$17.1B$17.7B$16.8B$18.5B
Shareholders' equity $25.4B$25.3B$25.0B$23.8B$24.1B
Net debt (βˆ’ = net cash) βˆ’$3.4Bβˆ’$2.0Bβˆ’$253Mβˆ’$466Mβˆ’$2.0B

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA summarises the numbers

  • Its return on capital was 5.8%: every 100 invested in the business earned about 6 in a year.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

KIRA summarises the numbers

  • Corteva passes 8 of 9 financial health tests (Piotroski F-score).

TestFY23FY24FY25
Net income is positive βœ“ βœ“ βœ“
Cash from operations is positive βœ“ βœ“ βœ“
Return on assets rose βœ• βœ“ βœ“
Cash from operations exceeds net income βœ“ βœ“ βœ“
Debt fell relative to assets βœ• βœ• βœ“
Current ratio rose βœ• βœ• βœ•
Share count didn't rise βœ“ βœ“ βœ“
Gross margin rose βœ“ βœ“ βœ“
Revenue rose relative to assets βœ• βœ• βœ“
F-score 5 / 96 / 98 / 9
Accruals ratio βˆ’2.4%βˆ’3.0%βˆ’5.5%
Altman Z'' 2.602.512.47

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

Price and value

What does the share cost, and how does it compare?

Value Corteva yourself

What could happen to the share if things go badly, normally or very well? Pick a story or make your own. These are examples, not forecasts or price targets.

KIRA summarises the numbers

  • At $11.95 a share, the company is worth $8.0B: 7.9 times its earnings of the last four quarters.

What if…? Five stories for the next 5 years

Tap one to see how it is built. Swipe for more.

Make your own scenario

Use the P/E of:

Share in 5 years

$25.84

+17% a year

If you put in $1,000 today: $2,162

At 17x, the share would still be worth today’s price in 5 years even if earnings fell 14.3% a year.

These are examples, not forecasts: nobody knows which will happen. Price in 5 years = earnings per share then Γ— the P/E then. Dividends are not included.

Advanced models Discounted cash flow and a one-year earnings multiple, with every assumption to tune.

Discounted cash flow

Value per share

β€”

Adds net cash of $2.0B and divides by 681.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

β€”

Reference multiples: today 8.2x Β· peers 29.6x Β· sector 20.6x.

In plain words: In the long run a share tends to follow two things: how much the company earns per share, and how many times those earnings the market is willing to pay (the P/E). Move those two levers and you see what the share could be worth. Different guesses give very different answers.

Similar companies

Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.

KIRA summarises the numbers

  • Corteva grew sales faster than 2 of its 4 similar companies.

    Its P/E is higher than 0 of 2.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Corteva CTVA $8.0B 2.9% β€” 16.2% 5.8% 7.9x 8
Mosaic MOS $5.6B 8.4% 6.8% βˆ’4.4% 2.5% β€” 8 Compare β†’
CF Industries CF $18.6B 19.3% 32.5% 25.4% 20.6% 9.0x 8 Compare β†’
FMC FMC $578M βˆ’18.3% βˆ’47.0% βˆ’3.0% βˆ’19.6% β€” 2 Compare β†’
Scotts Miracle-Gro SMG $3.5B βˆ’3.9% 10.5% 8.0% 13.4% 49.9x 6 Compare β†’

In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.

All figures

Every number, year by year.

8 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $14.3B $13.8B $14.2B $15.7B $17.5B $17.2B $16.9B $17.4B
Gross profit $4.3B $5.3B $5.7B $6.4B $7.0B $7.3B $7.4B $8.2B
Research and development $1.4B $1.1B $1.1B $1.2B $1.2B $1.3B $1.4B $1.5B
Interest expense $337M $136M $45.0M $30.0M $79.0M $233M $233M $180M
Pretax income βˆ’$6.8B βˆ’$316M $675M $2.3B $1.4B $1.1B $1.3B $1.7B
Income tax βˆ’$31.0M βˆ’$46.0M βˆ’$81.0M $524M $210M $152M $412M $484M
Net income βˆ’$5.1B βˆ’$959M $681M $1.8B $1.1B $735M $907M $1.1B
Diluted EPS βˆ’$6.76 βˆ’$1.28 $0.91 $2.37 $1.58 $1.03 $1.30 $1.60
Diluted shares 0.75B 0.75B 0.75B 0.74B 0.72B 0.71B 0.70B 0.68B
Cash flow
Cash from operations $483M $1.1B $2.1B $2.7B $872M $1.8B $2.1B $3.4B
Capital expenditure $1.5B $1.2B $475M $573M $605M $595M $597M $591M
Free cash flow βˆ’$1.0B βˆ’$93.0M $1.6B $2.2B $267M $1.2B $1.5B $2.8B
Depreciation and amortization $2.8B $1.6B $1.2B $1.2B $1.2B $1.2B $1.2B $1.2B
Acquisitions $0.0M $10.0M $0.0M $0.0M $0.0M $1.5B $0.0M $0.0M
Share buybacks $0.0M $25.0M $275M $950M $1.0B $756M $1.0B $1.1B
Dividends paid $0.0M $194M $388M $397M $418M $439M $458M $475M
Dividends and buybacks $0.0M $219M $663M $1.3B $1.4B $1.2B $1.5B $1.5B
Balance sheet
Cash and short-term investments $2.3B $1.8B $3.8B $4.5B $3.3B $2.7B $3.2B $4.5B
Total debt $7.9B $122M $1.1B $1.1B $1.3B $2.5B $2.7B $2.6B
Finance lease liabilities $92.0M $9.0M $5.0M $4.0M $3.0M $2.0M $0.0M $0.0M
Current assets $23.0B $13.5B $14.8B $15.5B $16.8B $16.3B $15.1B $17.3B
Current liabilities $13.3B $8.2B $8.5B $9.6B $10.7B $10.4B $10.4B $12.1B
Inventory $5.3B $5.0B $4.9B $5.2B $6.8B $6.9B $5.4B $5.7B
Property and equipment, net $4.5B $4.5B $4.4B $4.3B $4.3B $4.3B $4.1B $4.2B
Total assets $108.7B $42.4B $42.6B $42.3B $42.6B $43.0B $40.8B $42.8B
Total liabilities $33.5B $17.8B $17.6B $16.7B $17.1B $17.7B $16.8B $18.5B
Shareholders' equity $74.7B $24.3B $24.8B $25.4B $25.3B $25.0B $23.8B $24.1B
Margins
Gross margin 30.4% 38.1% 40.2% 41.1% 40.2% 42.4% 43.6% 47.3%
EBITDA margin βˆ’25.8% 10.3% 13.3% 23.1% 15.6% 14.7% 16.2% 17.7%
Net margin βˆ’35.5% βˆ’6.9% 4.8% 11.2% 6.6% 4.3% 5.4% 6.3%
FCF margin βˆ’7.1% βˆ’0.7% 11.2% 13.8% 1.5% 6.8% 9.2% 16.2%
Returns
Return on capital β€” βˆ’0.3% 3.2% 8.3% 5.6% 4.7% 4.2% 5.8%
Return on capital employed β€” βˆ’0.3% 2.1% 7.1% 4.7% 4.1% 4.8% 6.1%
Return on equity β€” βˆ’1.9% 2.8% 7.0% 4.5% 2.9% 3.7% 4.6%
Return on assets β€” βˆ’1.3% 1.6% 4.1% 2.7% 1.7% 2.2% 2.6%
Growth
Revenue growth β€” βˆ’3.1% 2.7% 10.1% 11.5% βˆ’1.3% βˆ’1.9% 2.9%
Net income growth β€” β€” β€” 158.3% βˆ’34.8% βˆ’35.9% 23.4% 20.6%
EPS growth β€” β€” β€” 160.4% βˆ’33.3% βˆ’34.8% 26.2% 23.1%
FCF growth β€” β€” β€” 35.6% βˆ’87.6% 339.7% 31.9% 81.9%
Share count change β€” 0.0% 0.2% βˆ’1.3% βˆ’2.3% βˆ’1.7% βˆ’2.2% βˆ’2.1%
Financial health
Net debt / EBITDA β€” βˆ’1.2x βˆ’1.4x βˆ’1.0x βˆ’0.7x βˆ’0.1x βˆ’0.2x βˆ’0.6x
Debt / equity 0.1x 0.0x 0.0x 0.0x 0.1x 0.1x 0.1x 0.1x
Interest coverage βˆ’19.2x βˆ’1.3x 16.0x 79.2x 19.1x 5.7x 6.5x 10.4x
Current ratio 1.7x 1.6x 1.7x 1.6x 1.6x 1.6x 1.5x 1.4x
Quick ratio 1.3x 1.0x 1.2x 1.1x 0.9x 0.9x 0.9x 1.0x
Capital allocation
Capex / revenue 10.5% 8.4% 3.3% 3.7% 3.5% 3.5% 3.5% 3.4%
Payouts / FCF β€” β€” 41.7% 62.5% 531.1% 101.8% 94.8% 54.9%
Quality scores
Piotroski F-score β€” β€” 7.0 7.0 4.0 5.0 6.0 8.0
Altman Z'' 2.5 2.2 2.6 3.0 2.8 2.6 2.5 2.5
Accruals ratio β€” βˆ’2.7% βˆ’3.3% βˆ’2.3% 0.7% βˆ’2.4% βˆ’3.0% βˆ’5.5%

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Source: SEC EDGAR XBRL filings (CIK 0001755672). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open